Piramal Pharma releases its Sustainability Report for FY 2023-24 under the theme, 'Building Resilience for a Sustainable Tomorrow'
PPL is dedicated to 'Operating Responsibly, Growing Sustainably,' with a vision to become a global leader in pharmaceuticals, driven by sustainability, inclusivity, and ethics. PPL's comprehensive strategy integrates sustainability principles across all operations and decision-making, focusing on 12 key areas and 28 material topics, supported by over 50 specific time-bound targets. This framework ensures PPL to effectively manage its sustainability responsibilities and drive meaningful impact across its global operations and value chain.
Key Highlights of the Report:
Responsible Operation
- PPL has made substantial progress in its energy efficiency efforts, with a 29% increase in renewable energy consumption. The company is committed to reducing absolute Scope 1 and 2 GHG emissions by 42% and Scope 3 emissions by 25% by FY 2030, using FY 2022 as the base year as validated by the Science Based Targets initiative (SBTi).
- Energy audits were completed at all sites, identifying opportunities for emission reductions through renewable energy sourcing (13%), low-carbon fuel switching (21%), and energy efficiency measures (7%).
- In both
India and theUK , 80% of non-hazardous waste was recycled and the company planted 2,440 saplings and implemented 15 water-saving micro-projects inIndia , resulting in 114 kilolitres of water savings per day.
Business Resilience
- PPL introduced a Sustainable Procurement Policy and revised its Supplier Code of Conduct, ensuring sustainable practices across its supply chain. Initiatives included the rollout of multi-factor authentication for O365 and enhanced data protection protocols for North American sites, as well as conducting Vulnerability Assessment and Penetration Testing (VAPT) scans. PPL continues to invest in a diverse, inclusive, and accessible workplace, with women representing 17.3% of its global workforce, including 72% of new campus hires.
- Through comprehensive safety and health programs, PPL maintains a Lost Time Injury Rate (LTIR) below 0.2 per 200,000 person-days.
- PPL rolled out a sustainability e-learning module for employees, and approximately 200 senior leaders in
India participated in Diversity, Inclusion, Belonging, and Accessibility (DIBA) workshops.
Quality & Excellence
- In FY 2024, PPL successfully completed 341 regulatory inspections, including 44 by the
U.S. FDA, with no critical observations. Additionally, close to 1,746 customer audits were conducted across global operations. - Automation has been a key driver of efficiency, with 70% of six major operational excellence KPIs automated across 11 sites. The company introduced 23 new robotic process automation (RPA) processes, bringing the total to 54 live processes.
Customer Centricity
- PPL achieved a customer satisfaction score of 85% for its
Contract Development and Manufacturing Organization (CDMO) business and 87% for itsConsumer Healthcare (CHG) business. The Net Promoter Scores (NPS) were 57 and 65 for the CDMO and CHG businesses, respectively.
The Sustainability report follows GRI standards and is aligned with SASSB and UNGC frameworks, underscoring PPL's commitment to sustainable growth, responsible capital allocation, and impactful stakeholder engagement. For more information, please refer to the full report available at https://www.piramalpharma.com/sustainability.
About Piramal Pharma Ltd:
For more information visit:
*Includes one facility through minority investment in Yapan Bio
Logo: https://mma.prnewswire.com/media/1855206/Piramal_Pharma_Limited_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/piramal-pharma-releases-its-sustainability-report-for-fy-2023-24-under-the-theme-building-resilience-for-a-sustainable-tomorrow-302267646.html
SOURCE